Improving oral absorption of samon calcitonin by trimyristin lipid nanoparticles

Journal of Biomedical Nanotechnology

Volumn 5, Issue 1, 2009, Pages 76-83

  Martins, S ^a   Silva, A C ^a   Ferreira, D C ^a   Souto, E B ^b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Hypocalcemic effect; Oral delivery; Protein delivery; Salmon calcitonin; sCT; SLN; Solid lipid nanoparticles; Trimyristin

Indexed keywords

HYPOCALCEMIC EFFECT; ORAL DELIVERY; PROTEIN DELIVERY; SALMON CALCITONIN; SCT; SLN; SOLID LIPID NANOPARTICLES; TRIMYRISTIN;

CALCIUM; DRUG PRODUCTS; EMULSIFICATION; EMULSIONS; SURFACE ACTIVE AGENTS;

NANOPARTICLES;

CALCIUM; POLOXAMER; SALCATONIN; SOLID LIPID NANOPARTICLE; TRIMYRISTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC FORCE MICROSCOPY; CALCIUM BLOOD LEVEL; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG RELEASE; EMULSION; EVALUATION; INTESTINE; LIPOSOMAL DELIVERY; MALE; NONHUMAN; PARTICLE SIZE; RAT; SCANNING ELECTROCHEMICAL MICROSCOPY; STOMACH PH; SURFACE PROPERTY;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; CALCITONIN; CRYSTALLIZATION; LIPIDS; MACROMOLECULAR SUBSTANCES; MALE; MATERIALS TESTING; MOLECULAR CONFORMATION; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, WISTAR; SALMON; SURFACE PROPERTIES; TRIGLYCERIDES;

EID: 67649798317     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.443     Document Type: Article

References (32)

1. E. B. Souto, R. D. Petersen, and R. H. Müller, Lipid nanoparticles with solid matrix for dermal delivery, Modified Release Drug Delivery Technology, edited by M. J. Rathbone, J. Hadgraft, M. S. Roberts, and M. Lane, Marcel Dekker Inc., New York, Basel, Hong-Kong (2008), Chap. 27, pp. 357-379.
2. R. H. Muller, K. Mader, and S. Gohla, Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur. J. Pharm. Biopharm. 50, 161 (2000).
3. B. Siekmann and K. Westesen, Submicron lipid suspensions (Solid lipid nanoparticles) versus lipid nanoemulsions: Similarities and differences, Submicron Emulsions in Drug Targeting and Delivery, edited by S. Benita, Harwood Academic Publishers, Amsterdam (1998), pp. 205-218.
4. R. H. Müller and J. S. Lucks, Arzneistoffträger aus festen Lipidteilchen - Feste Lipid Nanosphären (SLN), European Patent 0605497, Germany (1996).
5. M. R. Gasco, Method for producing solid lipid microspheres having a narrow size distribution, US Patent 5 250 236, Italy (1993).
6. A. J. Almeida and E. Souto, Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev. 59, 478 (2007).
7. V. Stipani, E. Gallucci, S. Micelli, V. Picciarelli, and R. Benz, Channel formation by salmon and human calcitonin in black lipid membranes. Biophys. J. 81, 3332 (2001).
8. M. Zaidi, A. M. Inzerillo, B. S. Moonga, P. J. Bevis, and C. L. Huang, Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30, 655 (2002).
9. M. Garcia-Fuentes, D. Torres, and M. J. Alonso, New surface- modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm. 296, 122 (2005).
10. T. Matsuyama, T. Morita, Y. Horikiri, H. Yamahara, and H. Yoshino, Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. J. Control. Release 115, 183 (2006).
11. M. Morishita and N. A. Peppas, Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today 11, 905 (2006).
12. J. H. Hamman, G. M. Enslin, and A. F. Kotze, Oral delivery of peptide drugs: Barriers and developments. BioDrugs 19, 165 (2005).
13. A. des Rieux, V. Fievez, M. Garinot, Y. J. Schneider, and V. Preat, Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 116, 1 (2006).
14. R. H. Muller, S. Runge, V. Ravelli, W. Mehnert, A. F. Thunemann, and E. B. Souto, Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int. J. Pharm. 317, 82 (2006).
15. A. Fasano, Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol. 16, 152 (1998).
16. H. Pinto-Alphandary, M. Aboubakar, D. Jaillard, P. Couvreur, and C Vauthier, Visualization of insulin-loaded nanocapsules: In vitro and in vivo studies after oral administration to rats. Pharm. Res. 20, 1071 (2003).
17. O. Borges, A. Cordeiro-da-Silva, S. G. Romeijn, M. Amidi, A. de Sousa, G. Borchard, and H. E. Junginger, Uptake studies in rat Peyer's patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Control. Release 114, 348 (2006).
18. S. Ribeiro, N. Hussain, and A. T. Florence, Release of DNA from dendriplexes encapsulated in PLGA nanoparticles. Int. J. Pharm. 298, 354 (2005).
19. M. García-Fuentes, D. Torres, and M. J. Alonso, Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf. B Biointerfaces 27, 159 (2002).
20. N. Zhang, Q. Ping, G. Huang, W. Xu, Y. Cheng, and X. Han, Lectin- modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327, 153 (2006).
21. X. Cao, S. T. Gibbs, L. Fang, H. A. Miller, C. P. Landowski, H. C. Shin, H. Lennernas, Y. Zhong, G. L. Amidon, L. X. Yu, and D. Sun, Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675 (2006).
22. H. S. Yoo and T. G. Park, Biodegradable nanoparticles containing protein-fatty acid complex for oral delivery of salmon calcitonin. J. Pharm. Sci. 93, 488 (2004).
23. E. B. Souto and R. H. Muller, Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J. Microencapsul. 23, 377 (2006).
24. C. Olbrich, O. Kayser, and R. H. Müller, Enzymatic degradation of Dynasan 114 SLN - Effect of surfactants and particle size. J. Nanoparticle Res. 4, 121 (2002).
25. F. Q. Hu, H. Yuan, H. H. Zhang, and M. Fang, Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization. Int. J. Pharm. 239, 121 (2002).
26. C. Olbrich, O. Kayser, and R. H. Muller, Lipase degradation of Dynasan 114 and 116 solid lipid nanoparticles (SLN) - Effect of surfactants, storage time and crystallinity. Int. J. Pharm. 237, 119 (2002).
27. C. Olbrich and R. H. Muller, Enzymatic degradation of SLN - Effect of surfactant and surfactant mixtures. Int. J. Pharm. 180, 31 (1999).
28. D. Sutoo and K. Akiyama, Neurochemical changes in mice following physical or psychological stress exposures. Behav. Brain Res. 134, 347 (2002).
29. D. Sutoo, K. Akiyama, and H. Takita, Behavioral changes in cold- stressed mice related to a central calcium-dependent-catecholamine synthesizing system. Pharmacol. Biochem. Behav. 40, 423 (1991).
30. M. Morishita, T. Goto, K. Nakamura, A. M. Lowman, K. Takayama, and N. A. Peppas, Novel oral insulin delivery systems based on complexation polymer hydrogels: Single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 110, 587 (2006).
31. M. Garcia-Fuentes, C. Prego, D. Torres, and M. J. Alonso, A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25, 133 (2005).
32. N. Salamat-Miller and T. P. Johnston, Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int. J. Pharm. 294, 201 (2005).